Dr. Weintraub’s primary clinical and research interests are centered around Preventative Cardiology, with a focus on the treatment and evaluation of lipid disorders (reducing elevated LDL-C and Triglycerides and increasing HDL-C), hypertension and global issues in the Metabolic Syndrome and Type II DM. He has worked with colleagues at the Lipid Center (Drs. Fisher, Schloss and Schwartzbard) in studies on the impact of combined statin and CETP antagonist, Endocannabinoid receptor antagonism, use of PPAR gamma agonists and a study soon to be initiated on the impact of fixed combination therapy for hypertension and elevated lipids on clinical outcomes and Carotid IMT.

Selected Publications:

1. Weintraub, HS. Treatment of Multiple-Risk Patients Using Combination Therapy to Treat Beyond LDL Lowering. Current Reports in Hypertension. 2005,7:265-70.
2. Cohen, JD; Blumenthal R; Horn HR; Weintraub, H; Weglicki, W. Torsades de Pointes, a Potential Complication of Diuretic-Induced Hypokalemia in Patients with Congestive Heart Failure: Conference Presentation of a Generic Patient. Current Therapeutic Research. 63, 12,p 1-7,12/2002.
3. Weintraub, Howard S, Beyond Blood Pressure-Effects of Angiotensin II Blockade. American Journal of Hypertension, April 2002, 15, #4, Supplement 1, p A238
4. Weintraub, H.S.; Commentary; Predictive value of Intimal-Medial Thickness. Cardiol Review. 2001
5. Weintraub, H.S.; Commentary. The case for ACE Inhibition. Cardiology Review. 2000; 17 (4):p. 37
6. Weintraub, H.S.; Clinical implications of endothelial dysfunction. Endothelial Function Forum. 1999; 16 (3) Supplement to Cardiology Review): p.1-6.
7. Weintraub, H.S.; ACE Inhibitors may reduce risk of CVD. Cardiology Review,1999; (8) p.6-8.
8. Weintraub, H.S., LVH and endothelial function: Impact on cardiovascular states. Endothelial Function Forum. 1999; 16 (9) (Supplement to Cardiology Review) p. 5-7.
9. Weintraub, H.S.; Commentary; Role of Inflammatory mediators. Cardiology Review. 1999; 16 (10): p. 39.